> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Revvity Targets Above-Market Growth And $5 Billion For Deals, Buybacks And Dividends
- URL: https://www.bullished.co/revvity-targets-above-market-growth-and-5-billion-for-deals-buybacks-and-dividends-f9b9ece1/
- Published: 2026-11-13T13:21:21.000Z
- Updated: 2026-11-13T13:21:21.000Z
- Description: The research-tools and diagnostics company pairs its growth ambitions with margin targets after cutting staff and facilities space.
- Author: Matteo Parrino
- Tags: SEC Filings, RVTY, Industry: Healthcare

[Revvity](https://www.bullished.co/tag/rvty/), which supplies laboratory instruments, test materials and scientific software, outlined a long-term growth plan Friday with about $5 billion available for acquisitions, buybacks and dividends through 2031\. Its investor presentation, accompanying an [SEC filing](https://www.sec.gov/Archives/edgar/data/0000031791/000162828026073578/pki-20261113.htm?ref=bullished.co), targets organic revenue growth of 6%–8%—2 percentage points above management’s estimate for its markets.

## Growth And A Smaller Footprint

Management’s [capital allocation plan](https://www.sec.gov/Archives/edgar/data/0000031791/000162828026073578/investorday2026presentat.htm?ref=bullished.co) calls for purchases that add capabilities to Life Sciences, continued share repurchases and preservation of the existing dividend. Revvity also intends to keep an investment-grade credit rating.

The company targets annual operating-margin improvement of 0.75 percentage points and double-digit growth in adjusted earnings per share. Its estimated 2026 adjusted operating margin is about 28.8%, with a longer-term ambition to reach roughly 35%.

Revvity has already [cut its workforce](https://www.sec.gov/Archives/edgar/data/0000031791/000162828026073578/investorday2026presentat.htm?ref=bullished.co) by about 16% and reduced global facilities space by about 25% from 2023 to 2026\. It removed management layers and integrated operations, while pursuing savings through vendor consolidation, insourcing and changes to packaging and shipping.

Share repurchases have changed the denominator for holders: the share count has fallen 12% since 2022\. Management’s preliminary assumptions for 2027 nevertheless use an unchanged share count.

## Software Connects The Lab To AI

Revvity’s Life Sciences business sells tools for cell, gene and protein research to drugmakers, biotech companies and research institutions. Diagnostics supplies hospitals and laboratories with testing instruments, materials and software, including prenatal and newborn screening products.

Management estimates 2026 revenue of about $2.9 billion, with about 85% coming from consumables, services and software. Its long-term organic growth targets are 7%–9% for Life Sciences and 5%–7% for Diagnostics.

Signals Software, the company’s platform for planning research, recording experiments and analyzing results, is expected to generate about $260 million in 2026 revenue. Estimated annual recurring revenue from cloud subscriptions exceeds $100 million, compared with about $10 million in 2020\. Cloud products are expected to account for about 35% of software revenue in 2026, versus about 5% in 2020.

Management targets 10%–12% growth in Signals’ annualized portfolio value—the annual value of its contracts. That is a different measure from the companywide organic revenue target.

Revvity’s AI argument spans both software and physical experiments. Management expects faster computational discovery to increase the need for laboratory evidence that tests predictions, while its software keeps experimental results connected to the next research decision.

President and CEO Prahlad Singh said in the accompanying press release, “we are confident in our ability to deliver [sustained, above-market growth](https://www.sec.gov/Archives/edgar/data/0000031791/000162828026073578/a2026investordaypressrelea.htm?ref=bullished.co) and long-term shareholder value.”

## 2027 Assumptions Come Before Formal Guidance

For 2027, management’s preliminary assumptions include about 6% organic growth, roughly 2 percentage points above estimated market growth. It also assumes about $85 million in net interest expense and a tax rate of about 19%.

The financial outlook uses the 2026 guidance issued Tuesday and excludes the China immunodiagnostics business, which Revvity has agreed to sell. That scope matters when comparing the growth ambitions with the company’s broader operations.

Revvity plans to issue formal 2027 guidance on its fourth-quarter earnings call.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — REVVITY, INC. (RVTY)](https://www.sec.gov/Archives/edgar/data/0000031791/000162828026073578/pki-20261113.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a2026investordaypressrelea.htm — REVVITY, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000031791/000162828026073578/a2026investordaypressrelea.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit investorday2026presentat.htm — REVVITY, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000031791/000162828026073578/investorday2026presentat.htm?ref=bullished.co) — SEC EDGAR
- [Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day](https://www.businesswire.com/news/home/20261113537627/en/Revvity-to-Showcase-Strategy-for-Powering-Scientific-Intelligence-at-2026-Investor-Day?ref=bullished.co) — businesswire.com

### More on Revvity

- [Revvity Raises 2026 Outlook As Adjusted Operating Margin Climbs To 28.7%](https://www.bullished.co/revvity-raises-2026-outlook-as-adjusted-operating-margin-climbs-to-28-7-b75ab61e/)
- [Revvity Says AI Demand Is Spreading Past Screening, Holds Detail For Its November 13 Investor Day](https://www.bullished.co/revvity-says-ai-demand-is-spreading-past-screening-holds-detail-for-its-november-13-5f27f96f/)

[All Revvity (RVTY) coverage →](https://www.bullished.co/tag/rvty/)